Generic Augmentin XR Availability

See also: Generic Augmentin ES-600

Augmentin XR is a brand name of amoxicillin/clavulanate, approved by the FDA in the following formulation(s):

AUGMENTIN XR (amoxicillin; clavulanate potassium - tablet, extended release;oral)

  • Manufacturer: DR REDDYS LABS INC
    Approval date: September 25, 2002
    Strength(s): 1GM;EQ 62.5MG BASE [RLD] [AB]

Has a generic version of Augmentin XR been approved?

A generic version of Augmentin XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Augmentin XR and have been approved by the FDA:

AMOXICILLIN AND CLAVULANATE POTASSIUM (amoxicillin; clavulanate potassium tablet, extended release;oral)

  • Manufacturer: SANDOZ
    Approval date: April 21, 2010
    Strength(s): 1GM;EQ 62.5MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Augmentin XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modified release pharmaceutical formulation comprising amoxycillin
    Patent 6,746,692
    Issued: June 8, 2004
    Inventor(s): Creighton P.; Conley & John A.; Roush & Kevin H.; Storm
    Assignee(s): Beecham Pharmaceuticals (Pte) Limited
    Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Patent expiration dates:
    • April 4, 2020
      ✓ 
      Drug product
  • Composition comprising amoxicillin and potassium clavulanate
    Patent 6,783,773
    Issued: August 31, 2004
    Inventor(s): Kevin H.; Storm & Creighton P.; Conley & John A.; Roush
    Assignee(s): Beecham Pharmaceuticals (Pte) Limited
    Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Patent expiration dates:
    • April 4, 2020
      ✓ 
      Drug product
  • Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
    Patent 6,878,386
    Issued: April 12, 2005
    Inventor(s): Conley; Creighton P. & Roush; John A. & Storm; Kevin H.
    Assignee(s): Beecham Pharmaceuticals (Pte) Limited
    Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Patent expiration dates:
    • April 4, 2020
      ✓ 
      Patent use: MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
  • Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan
    Patent 7,217,430
    Issued: May 15, 2007
    Inventor(s): Storm; Kevin H. & Conley; Creighton P. & Roush; John A.
    Assignee(s): Beecham Pharmaceuticals (Pte) Limited
    Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Patent expiration dates:
    • April 4, 2020
      ✓ 
      Patent use: MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
      ✓ 
      Drug product
  • Method of treating a bacterial infection
    Patent 7,250,176
    Issued: July 31, 2007
    Inventor(s): Storm; Kevin H. & Conley; Creighton P. & Roush; John A.
    Assignee(s): Beecham Pharmaceuticals (Pte) Limited
    Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
    Patent expiration dates:
    • April 4, 2020
      ✓ 
      Patent use: MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Severe allergies and anaphylaxis: Learn how epinephrine can save a life. Watch Video

Close
Hide
(web1)